-
1
-
-
4243660652
-
The spectrum of patient symptoms in ALS and symptom management
-
Heiman-Patterson TD, Rampal N, Brannagan, et al. The spectrum of patient symptoms in ALS and symptom management. Neurology 2000;56(8 Suppl 3):A199.
-
(2000)
Neurology
, vol.56
, Issue.8 SUPPL. 3
-
-
Heiman-Patterson, T.D.1
Rampal, N.2
Brannagan3
-
3
-
-
70249150025
-
Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease
-
Bedlack RS, Pastula DM, Hawes J, et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009;10:210-5.
-
(2009)
Amyotroph Lateral Scler
, vol.10
, pp. 210-215
-
-
Bedlack, R.S.1
Pastula, D.M.2
Hawes, J.3
-
5
-
-
7044254695
-
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial
-
Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-70.
-
(2004)
Neurology
, vol.63
, pp. 1364-1370
-
-
Brooks, B.R.1
Thisted, R.A.2
Appel, S.H.3
-
6
-
-
0035007860
-
A double-blind, placeho-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
-
DOI 10.1080/146608201300079364
-
Desnuelle C, Dib M, Garrel C, et al. Double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18. (Pubitemid 32472143)
-
(2001)
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
, vol.2
, Issue.1
, pp. 9-18
-
-
Desnuelle, C.1
Dib, M.2
Garrel, C.3
Favier, A.4
-
7
-
-
0029977337
-
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
-
Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-31. (Pubitemid 26161204)
-
(1996)
Lancet
, vol.347
, Issue.9013
, pp. 1425-1431
-
-
Lacomblez, L.1
Bensimon, G.2
Leigh, P.N.3
Guillet, P.4
Meininger, V.5
-
8
-
-
10544254257
-
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
-
WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group
-
Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-8.
-
(1996)
Neurology
, vol.47
, pp. 1383-1388
-
-
Miller, R.G.1
Moore, D.2
Young, L.A.3
-
9
-
-
0035836649
-
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
-
Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-8.
-
(2001)
Neurology
, vol.56
, pp. 843-848
-
-
Miller, R.G.1
Moore, D.H.2
Gelinas, D.F.3
-
10
-
-
2342430778
-
Survey of cannabis use in patients with amyotrophic lateral sclerosis
-
Amtmann D, Weydt P, Johnson KL, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95-104. (Pubitemid 38560946)
-
(2004)
American Journal of Hospice and Palliative Medicine
, vol.21
, Issue.2
, pp. 95-104
-
-
Amtmann, D.1
Weydt, P.2
Johnson, K.L.3
Jensen, M.P.4
Carter, G.T.5
-
12
-
-
0037218316
-
Therapeutic potential of cannabinoids in CNS disease
-
DOI 10.2165/00023210-200317030-00004
-
Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202. (Pubitemid 36286534)
-
(2003)
CNS Drugs
, vol.17
, Issue.3
, pp. 179-202
-
-
Croxford, J.L.1
-
13
-
-
0027366473
-
Muscle cramp as the result of impaired GABA function - An electrophysiological and pharmacological observation
-
DOI 10.1002/mus.880161113
-
Obi T, Mizoguchi K, Matsuoka H, et al. Muscle cramp as the result of impaired GABA function - an electrophysiological and pharmacological observation. Muscle Nerve 1993;16:1228-31. (Pubitemid 23304861)
-
(1993)
Muscle and Nerve
, vol.16
, Issue.11
, pp. 1228-1231
-
-
Obi, T.1
Mizoguchi, K.2
Matsuoka, H.3
Takatsu, M.4
Nishimura, Y.5
-
14
-
-
0028076338
-
Motor neuron 'bistability.' A pathogenetic mechanism for cramps and myokymia
-
Baldissera F, Cavallari P, Dworzak F. Motor neuron 'bistability.' A pathogenetic mechanism for cramps and myokymia. Brain 1994;117:929-39.
-
(1994)
Brain
, vol.117
, pp. 929-939
-
-
Baldissera, F.1
Cavallari, P.2
Dworzak, F.3
-
15
-
-
34548750944
-
Reflex inhibition of normal cramp following electrical stimulation of the muscle tendon
-
Khan SI, Burne JA. Reflex inhibition of normal cramp following electrical stimulation of the muscle tendon. J Neurophysiol 2007;98:1102-7.
-
(2007)
J Neurophysiol
, vol.98
, pp. 1102-1107
-
-
Khan, S.I.1
Burne, J.A.2
-
16
-
-
0033679502
-
Afterdischarge activity in neuropathic patients with frequent muscle cramps
-
Parisi L, Serrao M, Rossi P, et al. Afterdischarge activity in neuropathic patients with frequent muscle cramps. Acta Neurol Scand 2000;102:359-62.
-
(2000)
Acta Neurol Scand
, vol.102
, pp. 359-362
-
-
Parisi, L.1
Serrao, M.2
Rossi, P.3
-
17
-
-
33745418427
-
Axonal excitability properties in amyotrophic lateral sclerosis
-
DOI 10.1016/j.clinph.2006.04.016, PII S1388245706001799
-
Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006;117:1458-66. (Pubitemid 43947716)
-
(2006)
Clinical Neurophysiology
, vol.117
, Issue.7
, pp. 1458-1466
-
-
Vucic, S.1
Kiernan, M.C.2
-
18
-
-
34047276467
-
Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction
-
DOI 10.1111/j.1460-9568.2007.05422.x
-
Newman Z, Malik P, Wu TY, et al. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci 2007;25:1619-30. (Pubitemid 46549999)
-
(2007)
European Journal of Neuroscience
, vol.25
, Issue.6
, pp. 1619-1630
-
-
Newman, Z.1
Malik, P.2
Wu, T.-Y.3
Ochoa, C.4
Watsa, N.5
Lindgren, C.6
-
19
-
-
39049161976
-
Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: Implications for excitotoxicity
-
DOI 10.1111/j.1460-9568.2008.06041.x
-
Zhao P, Ignacio S, Beattie EC, et al. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosc 2008;27:572-9. (Pubitemid 351246277)
-
(2008)
European Journal of Neuroscience
, vol.27
, Issue.3
, pp. 572-579
-
-
Zhao, P.1
Ignacio, S.2
Beattie, E.C.3
Abood, M.E.4
-
21
-
-
78249275162
-
Treatment of cramps in amyotrophic lateral sclerosis/motor neuron disease. (Protocol)
-
Weber M, Feinberg D. Treatment of cramps in amyotrophic lateral sclerosis/motor neuron disease. (Protocol). Cochrane Database Sys Rev 2003.
-
(2003)
Cochrane Database Sys Rev
-
-
Weber, M.1
Feinberg, D.2
-
22
-
-
0032692481
-
The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function
-
DOI 10.1016/S0022-510X(99)00210-5, PII S0022510X99002105
-
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21. (Pubitemid 29502501)
-
(1999)
Journal of the Neurological Sciences
, vol.169
, Issue.1-2
, pp. 13-21
-
-
Cedarbaum, J.M.1
Stambler, N.2
Malta, E.3
Fuller, C.4
Hilt, D.5
Thurmond, B.6
Nakanishi, A.7
-
24
-
-
0028203293
-
The sleep disorders questionnaire. I: Creation and multivariate structure of SDQ
-
Douglass AB, Bornstein R, Nino-Murcia G, et al. The sleep disorders questionnaire. I: Creation and multivariate structure of SDQ. Sleep 1994;17:160-7.
-
(1994)
Sleep
, vol.17
, pp. 160-167
-
-
Douglass, A.B.1
Bornstein, R.2
Nino-Murcia, G.3
-
25
-
-
26844561209
-
The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) appetite scale in veteran cancer patients
-
Chang VT, Xia Q, Kasimis B. The functional assessment of anorexia/cachexia therapy (FAACT) appetite scale in veteran cancer patients. J Support Oncol 2005;3:377-82. (Pubitemid 41448264)
-
(2005)
Journal of Supportive Oncology
, vol.3
, Issue.5
, pp. 377-382
-
-
Chang, V.T.1
Xia, Q.2
Kasimis, B.3
-
26
-
-
0020527558
-
The hospital anxiety and depression scale
-
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
-
(1983)
Acta Psychiatr Scand
, vol.67
, pp. 361-370
-
-
Zigmond, A.S.1
Snaith, R.P.2
-
27
-
-
25444530723
-
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
-
DOI 10.1212/01.wnl.0000176753.45410.8b
-
Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9. (Pubitemid 41362120)
-
(2005)
Neurology
, vol.65
, Issue.6
, pp. 812-819
-
-
Rog, D.J.1
Nurmikko, T.J.2
Friede, T.3
Young, C.A.4
-
28
-
-
20844441058
-
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
-
Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-50. (Pubitemid 39350025)
-
(2004)
Neurology
, vol.63
, Issue.7
, pp. 1245-1250
-
-
Carroll, C.B.1
Bain, P.O.2
Teare, L.3
Liu, X.4
Joint, C.5
Wroath, C.6
Parkin, S.G.7
Fox, P.8
Wright, D.9
Hobart, J.10
Zajicek, J.P.11
-
29
-
-
1842580669
-
The effect of cannabis on tremor in patients with multiple sclerosis
-
Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-9. (Pubitemid 38456503)
-
(2004)
Neurology
, vol.62
, Issue.7
, pp. 1105-1109
-
-
Fox, P.1
Bain, P.G.2
Glickman, S.3
Carroll, C.4
Zajicek, J.5
-
30
-
-
0031692812
-
Urinary excretion half-life of 11-nor-9-carboxy-delta9- tetrahydrocannabinol in humans
-
Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy- delta9-tetrahydrocannabinol in humans. Ther Drug Monit 1998;20:570-6.
-
(1998)
Ther Drug Monit
, vol.20
, pp. 570-576
-
-
Huestis, M.A.1
Cone, E.J.2
-
31
-
-
0032820058
-
9- tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users
-
Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxydelta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999;23:323-32. (Pubitemid 29418298)
-
(1999)
Journal of Analytical Toxicology
, vol.23
, Issue.5
, pp. 323-332
-
-
Smith-Kielland, A.1
Skuterud, B.2
Morland, J.3
-
32
-
-
33845683331
-
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
-
DOI 10.1096/fj.05-4743fje
-
Bilsland LG, Dick JR, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006;20:1003-5. (Pubitemid 44943930)
-
(2006)
FASEB Journal
, vol.20
, Issue.7
-
-
Bilsland, L.G.1
Dick, J.R.T.2
Pryce, G.3
Petrosino, S.4
Di Marzo, V.5
Baker, D.6
Greensmith, L.7
-
33
-
-
0035437865
-
Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity
-
van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-9.
-
(2001)
J Neurosci
, vol.21
, pp. 6475-6479
-
-
Van Der Stelt, M.1
Veldhuis, W.B.2
Bar, P.R.3
-
34
-
-
2442484678
-
Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid
-
DOI 10.1080/14660820310016813
-
Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33-9. (Pubitemid 38618733)
-
(2004)
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
, vol.5
, Issue.1
, pp. 33-39
-
-
Raman, C.1
McAllister, S.D.2
Rizvi, G.3
Patel, S.G.4
Moore, D.H.5
Abood, M.E.6
-
35
-
-
33947278309
-
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset
-
Shoemaker JL, Seely KA, Reed RL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101:87-98.
-
(2007)
J Neurochem
, vol.101
, pp. 87-98
-
-
Shoemaker, J.L.1
Seely, K.A.2
Reed, R.L.3
-
36
-
-
26444608731
-
Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
-
DOI 10.1080/14660820510030149
-
Weydt P, Hong S, Witting A, et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:182-4. (Pubitemid 41419206)
-
(2005)
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
, vol.6
, Issue.3
, pp. 182-184
-
-
Weydt, P.1
Hong, S.2
Witting, A.3
Moller, T.4
Stella, N.5
Kliot, M.6
-
37
-
-
33645224970
-
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord
-
Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006;6:12.
-
(2006)
BMC Neurol
, vol.6
, pp. 12
-
-
Yiangou, Y.1
Facer, P.2
Durrenberger, P.3
-
38
-
-
77952624283
-
Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis
-
Rossi S, De Chiara V, Musella A, et al. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;19:1-8.
-
(2009)
Amyotroph Lateral Scler
, vol.19
, pp. 1-8
-
-
Rossi, S.1
De Chiara, V.2
Musella, A.3
|